Onco-immunological Aspect of COVID-19: Current Progress and Percep-tions | Coronaviruses; 3(2):3-5, 2022. | EMBASE

Contenido principal 1 Búsqueda 2 Pie de página 3

+A A -A Alto contraste

Base de datos de la OMS sobre COVID-19

Noticias/Actualización/Ayuda

Búsqueda Avanzada

The WHO Covid-19 Research Database is a resource created in response to the Public Health Emergency of International Concern (PHEIC). Its content remains searchable and spans the time period March 2020 to June 2023. Since June 2023, manual updates to the database have been discontinued.

Onco-immunological Aspect of COVID-19: Current Progress and Percep-tions

Ray, S. K.; Mukherjee, S..

Coronaviruses ; 3(2):3-5, 2022.

Artículo en Inglés | EMBASE | ID: covidwho-2277921

Palabras clave

biomarkers, cancer, covid-19, cytokine release syndrome, immunotherapy, onco-immune response, allogeneic hematopoietic stem cell transplantation, autoimmune disease, cancer chemotherapy, cancer control, cancer growth, cancer immunotherapy, cancer patient, cancer prognosis, cancer therapy, CD4 lymphocyte count, CD4+ T lymphocyte, chimeric antigen receptor T-cell immunotherapy, coronavirus disease 2019, cytotoxic T lymphocyte, disease severity, drug repositioning, editorial, hairy cell leukemia, human, hypertension, immune response, immune system, immunosuppressive treatment, incidence, innate immunity, Kaposi sarcoma, liver cell carcinoma, lung cancer, lymphocyte count, lymphocytopenia, melanoma, myeloid-derived suppressor cell, myeloma/dt [Drug Therapy], neutrophil count, neutrophil lymphocyte ratio, pathogenicity, platelet count, pneumonia, randomized controlled trial (topic), regulatory T lymphocyte, renal cell carcinoma, Severe acute respiratory syndrome coronavirus 2, Th17 cell, tumor associated leukocyte, tumor immunity, virus load, virus replication, acalabrutinib/ct [Clinical Trial], alpha2b interferon/ec [Endogenous Compound], angiotensin converting enzyme 2/ec [Endogenous Compound], antineoplastic agent, baricitinib/ct [Clinical Trial], beta1b interferon/ec [Endogenous Compound], bevacizumab/ct [Clinical Trial], biological marker/ec [Endogenous Compound], bispecific antibody/ec [Endogenous Compound], Bruton tyrosine kinase/ec [Endogenous Compound], C reactive protein/ec [Endogenous Compound], corticosteroid/ct [Clinical Trial], creatinine/ec [Endogenous Compound], dehydrodidemnin B/ct [Clinical Trial], dehydrodidemnin B/dt [Drug Therapy], dexamethasone/ct [Clinical Trial], gamma interferon/ec [Endogenous Compound], immune checkpoint inhibitor/ct [Clinical Trial], interleukin 6/ec [Endogenous Compound], Janus kinase inhibitor/ct [Clinical Trial], nivolumab/ct [Clinical Trial], pembrolizumab/ct [Clinical Trial], programmed death 1 ligand 1/ec [Endogenous Compound], recombinant interferon/ec [Endogenous Compound], ruxolitinib/ct [Clinical Trial], T lymphocyte receptor/ec [Endogenous Compound], toll like receptor 3/ec [Endogenous Compound], tumor necrosis factor/ec [Endogenous Compound], vasculotropin/ec [Endogenous Compound], vasculotropin receptor 2/ec [Endogenous Compound], zotatifin/ct [Clinical Trial], zotatifin/dt [Drug Therapy]

Buscar en Google

Texto completo: Disponible Colección: Bases de datos de organismos internacionales Base de datos: EMBASE Idioma: Inglés Revista: Coronaviruses Año: 2022 Tipo del documento: Artículo

Similares

MEDLINE

LILACS

LIS

Buscar en Google

Texto completo: Disponible Colección: Bases de datos de organismos internacionales Base de datos: EMBASE Idioma: Inglés Revista: Coronaviruses Año: 2022 Tipo del documento: Artículo